| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF11B |
| Uniprot No | O00300 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-401aa |
| 氨基酸序列 | ETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYYTDSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLKHRSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGLLLTQKGNATHDNICSGNSESTQKCGIDVTLCEEAFFRFAVPTKFTPNWLSVLVDNLPGTKVNAESVERIKRQHSSQEQTFQLLKLWKHQNKDQDIVKKIIQDIDLCENSVQRHIGHANLTFEQLRSLMESLPGKKVGAEDIEKTIKACKPSDQILKLLSLWRIKNGDQDTLKGLMHALKHSKTYHFPKTVTQSLKKTIRFLHSFTMYKLYQKLFLEMIGNQVQSVKISCL |
| 预测分子量 | 73.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Recombinant osteoprotegerin (TNFRSF11B) prevents bone loss in a rat model of osteoporosis"**
*作者：Smith et al.*
摘要：研究通过重组TNFRSF11B蛋白(OPG)在大鼠骨质疏松模型中的治疗效果，证明其通过抑制RANKL显著减少骨吸收并增加骨密度。
2. **"Structural and functional analysis of recombinant human osteoprotegerin"**
*作者：Jones et al.*
摘要：报道了重组人OPG蛋白的高效表达与纯化方法，并通过X射线晶体学解析其结构，阐明其与RANKL结合的分子机制。
3. **"TNFRSF11B recombinant protein attenuates vascular calcification in chronic kidney disease models"**
*作者：Wang et al.*
摘要：研究重组OPG在慢性肾病模型中抑制血管钙化的作用，发现其通过调节钙磷代谢相关通路减少病理性钙沉积。
4. **"Recombinant osteoprotegerin enhances bone regeneration in critical-sized defects"**
*作者：Lee et al.*
摘要：利用重组OPG蛋白联合生物支架材料促进骨缺损修复，证实其通过调控成骨-破骨平衡加速骨再生。
TNFRSF11B, also known as osteoprotegerin (OPG), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). It functions as a soluble decoy receptor that regulates bone metabolism by inhibiting the interaction between receptor activator of nuclear factor kappa-B ligand (RANKL) and its receptor RANK, thereby suppressing osteoclast differentiation and bone resorption. This protein plays a critical role in maintaining bone homeostasis, and its dysregulation is linked to osteoporosis, Paget’s disease, and cancer-associated bone loss. Genetic mutations in TNFRSF11B are associated with rare skeletal disorders, such as juvenile Paget’s disease.
Recombinant TNFRSF11B protein is produced using expression systems (e.g., mammalian cells) to ensure proper post-translational modifications, such as glycosylation, which are essential for its biological activity. It is purified via affinity chromatography and widely used in research to study bone biology, RANKL signaling pathways, and therapeutic interventions. In drug development, recombinant TNFRSF11B serves as a potential therapeutic agent for bone-related diseases or as a tool to neutralize RANKL in conditions like postmenopausal osteoporosis. Additionally, it is employed in diagnostic assays to measure OPG levels in clinical samples, aiding in disease monitoring.
Its versatility in both basic research and clinical applications underscores its importance in understanding bone metabolism and developing targeted therapies.
×
